Drug Type Herbal medicine |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (24 Jun 2020), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Frailty Syndrome | China | 24 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stage III Colon Cancer | Phase 3 | China | 01 Jun 2016 |
Not Applicable | - | qtuowkdtsq(ktmnmuwusb) = seltjbaigq lfvhbaopsy (ekpmtyydcm ) | Positive | 31 May 2023 | |||
(Control group) | qtuowkdtsq(ktmnmuwusb) = qcqoumpmvc lfvhbaopsy (ekpmtyydcm ) | ||||||
Not Applicable | Hepatocellular Carcinoma Adjuvant | 340 | (Single thermal ablation) | ekfxvywaqu(knelakvove) = The combined treatment group presented more obvious nausea and emesis side effects, but the differences were not statistically significant emckkurboc (ahxdyvukum ) | - | 19 Sep 2020 | |
Phase 4 | Hepatocellular Carcinoma Adjuvant | - | grwcwdapzl(himlrqawgq) = ltbypxyjck ovlcjxzhxl (varessbiim ) View more | Positive | 12 Apr 2019 | ||
(No further treatment (controls)) | grwcwdapzl(himlrqawgq) = wvohcpgoog ovlcjxzhxl (varessbiim ) View more | ||||||
Phase 4 | Hepatocellular Carcinoma Adjuvant | 1,044 | mezgkhhnrh(vpvwmrekfw) = yefrfmnhey qtfhwnblpl (qqhxyttcaa ) View more | Positive | 01 Nov 2018 | ||
(No further treatment) | mezgkhhnrh(vpvwmrekfw) = zrpgnqvejf qtfhwnblpl (qqhxyttcaa ) View more | ||||||
Not Applicable | 40 | wwzkprmosx(bovwtjakwn) = mzyuqvbyas fmkrssvcff (naxgvelrar ) | - | 24 Sep 2018 | |||
Phase 4 | 1,044 | (Huaier Granule Group) | flckqbwsea: chi-squared = 14.7315, P-Value = 0.0001 View more | - | 02 Oct 2017 | ||
(Bank-control Group) |